In a peer-reviewed study published in the British Journal of Pharmacology, several cannabinoids — including non-psychoactive cannabidiol (CBD), cannabigerol (CBG) and cannabidivarin (CBV) — appear to have the ability to “switch off” uncontrolled skin cell growth. This kind of uncontrolled growth is a factor in skin cancers and skin allergies. From the Truth on Pot article (emphasis ours):
- In the study, researchers recorded the effects of three cannabinoids – cannabidiol (CBD), cannabigerol (CBG) and cannabidivarin (CBV) – on human skin cell lines. CBD was found to be the most effective at targeting unwanted DNA activity, followed by CBG. While THC has also been suggested as an effective therapy for skin allergies, research is beginning to focus on compounds in marijuana that can’t get you high – which may be more appealing to patients.
The study’s authors state that in addition to appearing to halt detrimental DNA activity that is at the core of skin cancer and other skin diseases, phytocannabinoids like CBD may represent a new class of substances that could help turn off unwanted gene activity across the board:
- The authors also conclude that the potential to switch off gene activity may “extend well-beyond skin disorders” to diseases like multiple sclerosis and other forms of cancer.
Credit to TruthOnPot.com for the story. Read the full study in the British Journal of Pharmacology.
